Meta- analysis revealed few clinical ly relevant and statistically significant benefits of " add-on " therapies on exercise performance compared with exercise training .
The aim of this review was to identify the effectiveness of therapies added on to conventional exercise training to maximise exercise capacity in patients with chronic obstructive pulmonary disease ( COPD ) .
Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases.
A study was undertaken to determine the usefulness of ubidecarenone in pulmonary rehabilitation in exercise training programs in the management of chronic obstructive pulmonary disease ( COPD ) . The subjects were 20 patients with COPD who had been participating in an exercise training program for at least four weeks . The patients were r and omly assigned either to receive 50 mg of oral ubidecarenone daily or to enter a control group during the program .  Oxygen consumption , expired volume , and heart rate were measured during exercise tests before and after training . Maximum oxygen consumption increased 13 % in the ubidecarenone-treated patients and 7 % in the controls , and maximum expired volume increased 10 % in each group . The increases were significant in the ubidecarenone group but not in the controls . Heart rate increased 2 % in both groups . It is concluded that ubidecarenone deserves further evaluation in exercise training programs for patients with COPD
Meta- analysis revealed few clinical ly relevant and statistically significant benefits of " add-on " therapies on exercise performance compared with exercise training .
The aim of this review was to identify the effectiveness of therapies added on to conventional exercise training to maximise exercise capacity in patients with chronic obstructive pulmonary disease ( COPD ) .